Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™

Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer. This double blind, placebo-controlled Phase 1 study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of PRTX007 in […]
Anavo Therapeutics to Establish R&D Hub in World-Leading Cancer Research Cluster

Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced that the company has partnered with BioLabs Global, a developer and operator of premium co-working laboratories in the U.S. and Europe, to establish its R&D center as one of the first tenants at the newly established BioLabs life-sciences […]
Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvina LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces […]
Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology

Karl-Heinz Altmann, Andrew Mortlock and Gregg Siegal to join Anavo’s SAB Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced three key appointments to its Scientific Advisory Board in the persons of Karl-Heinz Altmann, currently Full Professor of Pharmaceutical Sciences at ETH Zurich and Head of the […]
Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

Seed round was led by M Ventures and INKEF Capital, and co-led by Taiho Ventures and Bioqube Ventures Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted today with a EUR 20 million (approx. $24 million) seed financing. Anavo’s mission is to pioneer systematic drug discovery and development […]
Primmune Therapeutics Strengthens Leadership Team with Key Appointments

Today, Primmune Therapeutics announced the appointment of Rich Daniels as Chief Operating Officer, Scott Zook as Senior Vice President, Global Manufacturing and Randy Adams as Senior Advisor, Commercial Development. “The appointments of Rich, Scott and Randy to the team build on the recent close of our Series A financing to support the development of PRTX007 as a […]
Primmune Therapeutics Announces Close of Series A Financing

Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of the Series A financing raise to $31.4 million. These funds will be used to support the development of PRTX007, a novel orally-administered, small molecule […]
Bioqube Ventures welcomes two seasoned professionals

Bioqube Ventures, a European life sciences venture capital firm, today announces that Tom Heyman joins Bioqube Ventures as Operating Partner and Peter Verhaeghe will chair the LP and Advisory Committee of the Bioqube Factory Fund I. Bolstering the team with industry veterans Tom Heyman and Peter Verhaeghe will help steer the portfolio to optimal growth […]
Bioqube Ventures launches Bioqube Factory Fund I

Bioqube Ventures announces today the first closing of Bioqube Factory Fund I, a new early stage venture capital fund focused on the development of therapeutic assets and technology platforms in Europe. Bioqube Factory Fund I will be raised in two closings and has already secured an amount of 60 MEUR in its first round from […]